Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Route Of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Hunter Syndrome Treatment Market Growth & Trends
The global hunter syndrome treatment market size is expected treach a value of USD 1.78 billion by 2030, expanding at a CAGR of 5.3% from 2025 t2030, according ta new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected tdrive market growth over the forecast period.
Hunter syndrome, alsreferred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According tthe data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 t150,000 male births.
Presently, there are napproved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea.
Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected tsignificantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.
Hunter Syndrome Treatment Market Report Highlights
Hunter Syndrome Treatment Market Growth & Trends
The global hunter syndrome treatment market size is expected treach a value of USD 1.78 billion by 2030, expanding at a CAGR of 5.3% from 2025 t2030, according ta new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected tdrive market growth over the forecast period.
Hunter syndrome, alsreferred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According tthe data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 t150,000 male births.
Presently, there are napproved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea.
Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected tsignificantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.
Hunter Syndrome Treatment Market Report Highlights
- The intravenous segment led the market and accounted for the largest revenue share of 72.3% in 2024 attributed tits established effectiveness in delivering enzyme replacement therapies (ERT).
- Enzyme replacement therapy (ERT) led the market and accounted for the largest revenue share of 57.3% in 2024 driven by its ability taddress the deficiency of the enzyme iduronate-2-sulfatase.
- Hospitals held the dominant position in the market, accounting for the largest revenue share of 63.1% in 2024 attributed ttheir capacity tprovide comprehensive care and advanced medical resources.
- North America hunter syndrome treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed ta combination of advanced healthcare infrastructure and increasing awareness of rare diseases.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. Test
1.2.4. Type
1.2.5. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. HUNTER SYNDROME TREATMENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. HUNTER SYNDROME TREATMENT MARKET: TYPE BUSINESS ANALYSIS
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Enzyme Replacement Therapy (ERT)
4.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
4.5. Hematopoietic Stem Cell Transplant (HSCT)
4.5.1. Hematopoietic Stem Cell Transplant (HSCT) Market, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. HUNTER SYNDROME TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Intravenous
5.4.1. Intravenous Market, 2018 - 2030 (USD Million)
5.5. Intracerebroventricular (ICV)/ Intrathecal
5.5.1. Intracerebroventricular (ICV)/Intrathecal Market, 2018 - 2030 (USD Million)
CHAPTER 6. HUNTER SYNDROME TREATMENT MARKET: END USE BUSINESS ANALYSIS
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
6.5. Specialty Clinics
6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. HUNTER SYNDROME TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Competitive insights
7.4.2.4. U.S. hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Competitive insights
7.4.3.4. Canada hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework
7.4.4.3. Competitive insights
7.4.4.4. Mexico hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive insights
7.5.2.4. UK hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive insights
7.5.3.4. Germany hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive insights
7.5.4.4. France hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework
7.5.5.3. Competitive insights
7.5.5.4. Italy hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework
7.5.6.3. Competitive insights
7.5.6.4. Spain hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework
7.5.7.3. Competitive insights
7.5.7.4. Norway hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework
7.5.8.3. Competitive insights
7.5.8.4. Denmark hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key country dynamics
7.5.9.2. Regulatory framework
7.5.9.3. Competitive insights
7.5.9.4. Sweden hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive insights
7.6.2.4. Japan hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive insights
7.6.3.4. China hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive insights
7.6.4.4. India hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive insights
7.6.5.4. South Korea hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive insights
7.6.6.4. Australia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive insights
7.6.7.4. Thailand hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive insights
7.7.2.4. Brazil hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive insights
7.7.3.4. Argentina hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive insights
7.8.2.4. South Africa hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive insights
7.8.3.4. Saudi Arabia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework
7.8.4.3. Competitive insights
7.8.4.4. UAE hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Regulatory framework
7.8.5.3. Competitive insights
7.8.5.4. Kuwait hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Takeda Pharmaceutical Company Limited
8.5.1.1. Overview
8.5.1.2. Financial performance
8.5.1.3. Type benchmarking
8.5.1.4. Strategic initiatives
8.5.2. F. Hoffmann-La Roche Ltd.
8.5.2.1. Overview
8.5.2.2. Financial performance
8.5.2.3. Type benchmarking
8.5.2.4. Strategic initiatives
8.5.3. Abbott
8.5.3.1. Overview
8.5.3.2. Financial performance
8.5.3.3. Type benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Denali Therapeutics
8.5.4.1. Overview
8.5.4.2. Financial performance
8.5.4.3. Type benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Medtronic
8.5.5.1. Overview
8.5.5.2. Financial performance
8.5.5.3. Type benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Johnson & Johnson Services, Inc.
8.5.6.1. Overview
8.5.6.2. Financial performance
8.5.6.3. Type benchmarking
8.5.6.4. Strategic initiatives
8.5.7. GSK Plc.
8.5.7.1. Overview
8.5.7.2. Financial performance
8.5.7.3. Type benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bayer AG
8.5.8.1. Overview
8.5.8.2. Financial performance
8.5.8.3. Type benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Zimmer Biomet
8.5.9.1. Overview
8.5.9.2. Financial performance
8.5.9.3. Type benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Stryker Corporation
8.5.10.1. Overview
8.5.10.2. Financial performance
8.5.10.3. Type benchmarking
8.5.10.4. Strategic initiatives
8.5.11. Homology Medicines, Inc.
8.5.11.1. Overview
8.5.11.2. Financial performance
8.5.11.3. Type benchmarking
8.5.11.4. Strategic initiatives
8.5.12. Novartis AG
8.5.12.1. Overview
8.5.12.2. Financial performance
8.5.12.3. Type benchmarking
8.5.12.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. Test
1.2.4. Type
1.2.5. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. HUNTER SYNDROME TREATMENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. HUNTER SYNDROME TREATMENT MARKET: TYPE BUSINESS ANALYSIS
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Enzyme Replacement Therapy (ERT)
4.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
4.5. Hematopoietic Stem Cell Transplant (HSCT)
4.5.1. Hematopoietic Stem Cell Transplant (HSCT) Market, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. HUNTER SYNDROME TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Intravenous
5.4.1. Intravenous Market, 2018 - 2030 (USD Million)
5.5. Intracerebroventricular (ICV)/ Intrathecal
5.5.1. Intracerebroventricular (ICV)/Intrathecal Market, 2018 - 2030 (USD Million)
CHAPTER 6. HUNTER SYNDROME TREATMENT MARKET: END USE BUSINESS ANALYSIS
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
6.5. Specialty Clinics
6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. HUNTER SYNDROME TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Competitive insights
7.4.2.4. U.S. hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Competitive insights
7.4.3.4. Canada hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework
7.4.4.3. Competitive insights
7.4.4.4. Mexico hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive insights
7.5.2.4. UK hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive insights
7.5.3.4. Germany hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive insights
7.5.4.4. France hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework
7.5.5.3. Competitive insights
7.5.5.4. Italy hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework
7.5.6.3. Competitive insights
7.5.6.4. Spain hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework
7.5.7.3. Competitive insights
7.5.7.4. Norway hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework
7.5.8.3. Competitive insights
7.5.8.4. Denmark hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key country dynamics
7.5.9.2. Regulatory framework
7.5.9.3. Competitive insights
7.5.9.4. Sweden hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive insights
7.6.2.4. Japan hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive insights
7.6.3.4. China hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive insights
7.6.4.4. India hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive insights
7.6.5.4. South Korea hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive insights
7.6.6.4. Australia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive insights
7.6.7.4. Thailand hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive insights
7.7.2.4. Brazil hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive insights
7.7.3.4. Argentina hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive insights
7.8.2.4. South Africa hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive insights
7.8.3.4. Saudi Arabia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework
7.8.4.3. Competitive insights
7.8.4.4. UAE hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Regulatory framework
7.8.5.3. Competitive insights
7.8.5.4. Kuwait hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Takeda Pharmaceutical Company Limited
8.5.1.1. Overview
8.5.1.2. Financial performance
8.5.1.3. Type benchmarking
8.5.1.4. Strategic initiatives
8.5.2. F. Hoffmann-La Roche Ltd.
8.5.2.1. Overview
8.5.2.2. Financial performance
8.5.2.3. Type benchmarking
8.5.2.4. Strategic initiatives
8.5.3. Abbott
8.5.3.1. Overview
8.5.3.2. Financial performance
8.5.3.3. Type benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Denali Therapeutics
8.5.4.1. Overview
8.5.4.2. Financial performance
8.5.4.3. Type benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Medtronic
8.5.5.1. Overview
8.5.5.2. Financial performance
8.5.5.3. Type benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Johnson & Johnson Services, Inc.
8.5.6.1. Overview
8.5.6.2. Financial performance
8.5.6.3. Type benchmarking
8.5.6.4. Strategic initiatives
8.5.7. GSK Plc.
8.5.7.1. Overview
8.5.7.2. Financial performance
8.5.7.3. Type benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bayer AG
8.5.8.1. Overview
8.5.8.2. Financial performance
8.5.8.3. Type benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Zimmer Biomet
8.5.9.1. Overview
8.5.9.2. Financial performance
8.5.9.3. Type benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Stryker Corporation
8.5.10.1. Overview
8.5.10.2. Financial performance
8.5.10.3. Type benchmarking
8.5.10.4. Strategic initiatives
8.5.11. Homology Medicines, Inc.
8.5.11.1. Overview
8.5.11.2. Financial performance
8.5.11.3. Type benchmarking
8.5.11.4. Strategic initiatives
8.5.12. Novartis AG
8.5.12.1. Overview
8.5.12.2. Financial performance
8.5.12.3. Type benchmarking
8.5.12.4. Strategic initiatives
